IP Library Granted Patent US 10,238,663
Granted Patent B2
US 10,238,663 · App. 15/643,857 · Granted Mar 26, 2019

Extended-release drug delivery compositions

Inventors: Nathan Dormer (Mission, KS); Cory Berkland (Lawrence, KS)
Assignee: ORBIS BIOSCIENCES, INC.
A61K31/573A61K9/0019A61K9/0046A61K9/10A61K9/1635A61K9/1647A61K31/43A61K31/711A61K31/713A61K38/38A61K47/10A61K47/26A61K47/32A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,663
App. No.
15/643,857
Granted
Mar 26, 2019
Kind
B2
Abstract

An extended-release drug delivery composition and method of administering the same is provided. The composition comprises microspheres loaded with a biologically-active agent and suspended in a soluble polymer capable of forming a film upon injection onto a biological surface.

Claims (12)

1. A method for providing an extended-release treatment to a subject, the method comprising injecting a composition onto a biological tissue of the subject suffering from sensorineural hearing loss no more than one time in a 14 day period, wherein the composition comprises a biologically-active agent dispersed in a film-forming agent, wherein the film-forming agent comprises water and polyvinyl alcohol (PVA), wherein the PVA is from about 5% to about 10% w/v of the film-forming agent, wherein the PVA has a molecular weight of 20,000 to 30,000 Daltons, wherein the film-forming agent is free of solvent.

2. The method of claim 1 further comprising the step of maintaining the subject in a fixed position following injection until the composition forms a film on the biological tissue.

3. The method of claim 1 , wherein the biological tissue is the middle ear.

4. The method of claim 1 , wherein the biological tissue is the round window membrane of the inner ear.

5. The method of claim 1 , wherein the step of injecting the composition is performed by an intratympanic injection.

6. The method of claim 1 , wherein the biological tissue is the middle ear, and wherein the biologically-active agent is a therapeutic compound used in the treatment of sensorineural hearing loss.

7. The method of claim 1 , wherein the composition further comprises a surfactant, wherein the surfactant is from about 0.5% to about 5% w/v of the film-forming agent.

8. The method of claim 7 , wherein the surfactant is selected from the group consisting of polysorbate 20, polysorbate 60, polysorbate 80 or sorbitan laurate.

9. The method of claim 7 , wherein the PVA is about 10% w/v of the film-forming agent and the surfactant is about 5% w/v of the composition.

10. The method of claim 1 wherein the PVA is about 88% hydrolyzed.

11. A method for providing an extended-release treatment to a subject, the method comprising injecting a composition onto a middle ear tissue of the subject no more than one time in a 14 day period, wherein the composition comprises a biologically-active agent dispersed in a film-forming agent, wherein the film-forming agent comprises water and polyvinyl alcohol (PVA), wherein the PVA is from about 5% to about 10% w/v of the film-forming agent, wherein the PVA has a molecular weight of 20,000 to 30,000 Daltons, and wherein the film-forming agent is free of solvent.

12. A method for providing an extended-release treatment to a subject, the method comprising injecting a composition onto a biological tissue of the subject no more than one time in a 14 day period, wherein the step of injecting the composition is performed by an intratympanic injection, wherein the composition comprises a biologically-active agent dispersed in a film-forming agent, wherein the film-forming agent comprises water and polyvinyl alcohol (PVA), wherein the PVA is from about 5% to about 10% w/v of the film-forming agent, wherein the PVA has a molecular weight of 20,000 to 30,000 Daltons, and wherein the film-forming agent is free of solvent.

Assignments (5)
CHANGE OF NAME Recorded Sep 24, 2020
From: ORBIS BIOSCIENCES, INC.
To: ADARE PHARMACEUTICALS USA, INC.
Reel/Frame 053868/0027 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAMES 037246/0313, 047807/0967, 053474/0276 Recorded Sep 22, 2020
From: BANK OF MONTREAL, AS COLLATERAL AGENT
To: ADARE PHARMACEUTICALS, INC.; ADARE DEVELOPMENT I, L.P.; ADARE PHARMACEUTICALS USA, INC.
Reel/Frame 053852/0697 →
SECURITY INTEREST Recorded Sep 22, 2020
From: ADARE PHARMACEUTICALS, INC.; ADARE PHARMACEUTICALS USA, INC.
To: CRESCENT AGENCY SERVICES LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 053849/0967 →
SECURITY INTEREST Recorded Aug 12, 2020
From: ADARE PHARMACEUTICALS USA, INC.
To: BANK OF MONTREAL
Reel/Frame 053474/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2019
From: DORMER, NATHAN; BERKLAND, CORY
To: ORBIS BIOSCIENCES, INC.
Reel/Frame 050883/0795 →
Continuity (3)
Continuation 14738174 · Jun 12, 2015
Provisional Application 62011380 · Jun 12, 2014
Related Publication 20170304320A1 · Oct 26, 2017